이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

심장 유육종증 다기관 전향적 코호트 (CHASM-CS)

2026년 10월 30일 업데이트: Ottawa Heart Institute Research Corporation

심장 유육종증 다기관 전향적 코호트 연구

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

연구 개요

상태

모병

정황

상세 설명

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

연구 유형

관찰

등록 (추정된)

1500

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Janine E Ryan, BA(H), CCRP
  • 전화번호: 17077 613-696-7000
  • 이메일: jryan@ottawaheart.ca

연구 연락처 백업

연구 장소

      • Sapporo, 일본, 060-8638
        • 모병
        • Hokkaido University
        • 연락하다:
        • 수석 연구원:
          • Ichizo Tsujino, MD
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 2T9
        • 모병
        • Libin Cardiovascular Institute of Alberta
        • 수석 연구원:
          • Russell Quinn, MD
        • 연락하다:
          • Russell Quinn, MD
      • Edmonton, Alberta, 캐나다, T6G 2B7
        • 모병
        • University of Alberta Hospital
        • 연락하다:
          • Tomascz Hruczkowski, MD
        • 수석 연구원:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 1M9
        • 모병
        • St. Paul's Hospital
        • 연락하다:
          • Shanta Chakrabarti, MD
        • 수석 연구원:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3H 3A7
        • 모병
        • QEII Health Sciences Center
        • 수석 연구원:
          • Ciorsti MacIntyre, MD
        • 연락하다:
          • Kim Anderson, MD
    • Ontario
      • Hamilton, Ontario, 캐나다, L8L 2X2
        • 모병
        • Hamilton Health Sciences Centre
        • 수석 연구원:
          • Jeff Healey, MD
        • 연락하다:
          • Gerard Cox, MD
        • 연락하다:
          • Jeff Healey, MD
      • London, Ontario, 캐나다, N6A 5A5
        • 모병
        • London Health Sciences Centre
        • 연락하다:
          • Lorne Gula, MD
        • 수석 연구원:
          • Lorne Gula, MD
      • Newmarket, Ontario, 캐나다, L3Y 2P9
        • 모병
        • Southlake Regional Health Centre
        • 연락하다:
          • Bernice Tsang, MD
        • 수석 연구원:
          • Bernice Tsang, MD
      • Ottawa, Ontario, 캐나다, K1Y 4W7
        • 모병
        • University of Ottawa Heart Institute
        • 연락하다:
        • 수석 연구원:
          • David Birnie, MD
        • 연락하다:
      • Toronto, Ontario, 캐나다, M5G 2C4
        • 모병
        • Toronto General Hospital
        • 연락하다:
          • Andrew Ha, MD
        • 수석 연구원:
          • Andrew Ha, MD
    • Quebec
      • Montreal, Quebec, 캐나다, H1T 1C8
        • 모병
        • Montreal Heart Institute
        • 연락하다:
          • Lena Rivard, MD
        • 수석 연구원:
          • Lena Rivard, MD
      • Montreal, Quebec, 캐나다, H3G 1A4
        • 모병
        • McGill University Health Centre
        • 연락하다:
          • Fiorella Rafti
        • 수석 연구원:
          • Martin L Bernier, MD
      • Montreal, Quebec, 캐나다, H2W 1T8
        • 아직 모집하지 않음
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • 연락하다:
          • Julie Fleury, RN
        • 수석 연구원:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina, Saskatchewan, 캐나다, S4P 0W5
        • 모병
        • Prairie Vascular Research Inc-Regina General Hospital
        • 연락하다:
        • 수석 연구원:
          • Andrea Lavoie, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Electrophysiology Service patients

설명

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Primary Outcome for ALL Patients
기간: Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

2차 결과 측정

결과 측정
측정값 설명
기간
Secondary Outcomes for ALL Patients
기간: Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
기간: Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
기간: Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
기간: Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
  • 수석 연구원: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
  • 수석 연구원: David Birnie, MD, Ottawa Heart Institute Research Corporation

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2012년 8월 1일

기본 완료 (추정된)

2027년 3월 1일

연구 완료 (추정된)

2035년 12월 1일

연구 등록 날짜

최초 제출

2011년 11월 10일

QC 기준을 충족하는 최초 제출

2011년 11월 18일

처음 게시됨 (추정된)

2011년 11월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • UOHI-04

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .